Shares of Pfizer Inc. PFE rallied 1.71% to $25.58 Wednesday, on what proved to be an all-around poor trading session for the ...

Pfizer is a Buy at low valuation but faces a 2030 patent cliff, COVID sales declines, and LOE risks. Click here to read an ...

SAN FRANCISCO, Jan 12 (Reuters) - Pfizer is preparing for ‌a ​consumer market for obesity drugs on ‌par with the booming ...

With partner Eli Lilly’s help, the radiopharmaceutical drugmaker priced one of the sector’s largest new stock offerings in ...

Pfizer is buying out Metsera for up to $10 billion after an acquisition battle with another pharma giant. Metsera's leading candidate could be an excellent way for Pfizer to enter the weight-loss drug ...

We recently published 12 Latest Stocks on Jim Cramer’s Radar. Pfizer Inc. (NYSE:PFE) is one of the stocks Jim Cramer recently discussed. Jim Cramer has discussed pharma giant Pfizer Inc. (NYSE:PFE) ...

Pfizer shares have emerged as a compelling contrarian investment opportunity as the pharmaceutical giant trades at historically attractive valuations following an extended period of market skepticism.

Pfizer offers a 7% dividend yield, providing steady income despite stagnant share performance in recent months. COVID-19 product sales have sharply declined, with Paxlovid down 55% and vaccine revenue ...

Novo Nordisk has launched a rival bid for U.S. obesity biotech firm Metsera, directly challenging an existing offer from Pfizer. The move, announced Thursday, escalates the competition between the two ...

Investors in Pfizer Inc (Symbol: PFE) saw new options begin trading today, for the December 5th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the PFE options ...

After its best day in nearly four years Tuesday, Pfizer stock gave an encore performance. Shares of the drugmaker closed up 6.8% as investors digested Tuesday's news that Pfizer would get a three-year ...